ArticleScientific reports2024

Derived neutrophil-to-lymphocyte ratio has the potential to predict safety and outcomes of durvalumab after chemoradiation in non-small cell lung cancer.

Akira Sugimoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.